Genetic polymorphism of cytochrome P4502C9 in a Caucasian and a black African population

被引:182
作者
Scordo, MG
Aklillu, E
Yasar, U
Dahl, ML
Spina, E
Ingelman-Sundberg, M [1 ]
机构
[1] Karolinska Inst, IMM, Div Mol Toxicol, Inst Environm Med, SE-17177 Stockholm, Sweden
[2] Huddinge Univ Hosp, Karolinska Inst, Div Clin Pharmacol, Dept Med Lab Sci & Technol, Stockholm, Sweden
[3] Univ Messina, Inst Pharmacol, I-98100 Messina, Italy
关键词
interethnic differences; losartan; poor metabolisers; warfarin;
D O I
10.1046/j.0306-5251.2001.01460.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims CYP2C9 is a major enzyme in human drug metabolism and the polymorphism observed in the corresponding gene may affect the therapeutic outcome during treatment with several drugs. The distribution of variant CYP2C9 alleles was therefore investigated in an Italian and an Ethiopian population. Methods Allele-specific PCR analysis was carried out in order to determine the frequencies of the two most common variant alleles, CYP2C9*2 and CYP2C9*3 in genomic DNA isolated from 157 Italians and 150 Ethiopians. Results The frequencies of CYP2C9*1 (80%), CYP2C9*2 (11%) and CYP2C9*3 (9%) found in the Italian population were similar to other Caucasian groups. However in the Ethiopian population CYP2C9*1, CYP2C9*2 and CYP2C9*3 were present at a frequency of 94, 4 and 2% respectively. The 95% confidence intervals in CYP2C9*1, CYP2C9*2 and CYP2C9*3 between Italians and Ethiopians were 0.098, 0.176, 0.040, 0.098 and 0.040, 0.098, respectively. Conclusions Our results indicate that the Ethiopian population has a unique relative distribution of the CYP2C9 alleles, which is not similar to any other ethnic group hitherto described.
引用
收藏
页码:447 / 450
页数:4
相关论文
共 21 条
  • [1] Ackermann E., 1997, European Journal of Clinical Pharmacology, V52, pA71
  • [2] Aklillu E, 1996, J PHARMACOL EXP THER, V278, P441
  • [3] Aynacioglu AS, 1999, BRIT J CLIN PHARMACO, V48, P409
  • [4] OXIDATION OF BENZO[A]PYRENE BY RECOMBINANT HUMAN CYTOCHROME-P450 ENZYMES
    BAUER, E
    GUO, ZY
    UENG, YF
    BELL, LC
    ZELDIN, D
    GUENGERICH, FP
    [J]. CHEMICAL RESEARCH IN TOXICOLOGY, 1995, 8 (01) : 136 - 142
  • [5] Gaedigk A, 2000, INT J CLIN PHARM TH, V38, P61
  • [6] Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients:: genetic analysis of the CYP2C9 locus
    Imai, J
    Ieiri, I
    Mamiya, K
    Miyahara, S
    Furuumi, H
    Nanba, E
    Yamane, M
    Fukumaki, Y
    Ninomiya, H
    Tashiro, N
    Otsubo, K
    Higuchi, S
    [J]. PHARMACOGENETICS, 2000, 10 (01): : 85 - 89
  • [7] Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment
    Ingelman-Sundberg, M
    Oscarson, M
    McLellan, RA
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 1999, 20 (08) : 342 - 349
  • [8] Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population
    Kimura, M
    Ieiri, I
    Mamiya, K
    Urae, F
    Higuchi, S
    [J]. THERAPEUTIC DRUG MONITORING, 1998, 20 (03) : 243 - 247
  • [9] A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: Association with diminished debrisoquine hydroxylase activity
    Masimirembwa, C
    Persson, I
    Bertilsson, L
    Hasler, J
    IngelmanSundberg, M
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 42 (06) : 713 - 719
  • [10] Cytochrome P4502C9: an enzyme of major importance in human drug metabolism
    Miners, JO
    Birkett, DJ
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 45 (06) : 525 - 538